CPHI Americas 2026: What's on the Agenda and Why It Matters

In June, Philadelphia will play host to one of the most important gatherings in the North American pharma supply chain. CPHI Americas brings together manufacturers, CDMOs, biotech firms, suppliers, and service providers for three days of conversation that tends to reflect exactly where the industry is and where it's heading. This year's agenda is a particularly honest one. The themes aren't aspirational talking points. They're responses to real pressure that organisations across the sector are already feeling.

‍

The regulatory picture has changed

The FDA has been one of the most talked-about topics in pharma this year, and not because things are running smoothly. Policy uncertainty, shifting enforcement priorities, and a broader rethink of how risk-based decision-making works in practice have left many organisations in a difficult position: trying to plan strategically while the regulatory ground keeps moving.

CPHI Americas is addressing this directly. A session titled "FDA in Flux: Navigating the New Regulatory Landscape" features Molly Klote, former director of the HHS Office for Human Research Protections, alongside Highlander Health co-founder Amy Abernethy. Alongside that, there's a broader conversation about onshoring pressures and what tighter domestic manufacturing expectations actually mean for companies built around global supply chains.

For anyone in regulatory affairs, quality, or compliance, these sessions will be worth prioritising. The goal isn't just staying informed. It's walking away with a clearer framework for how to make decisions when the rulebook is mid-revision.

‍

AI is moving from conversation to practice

Pharma has been talking about AI for long enough that the conversation itself has become a bit tired. What's different at CPHI Americas 2026 is that the sessions are getting more specific. The focus has shifted from what AI could do to how organisations are actually embedding it, from drug discovery workflows led by teams like UCB's, to the digital infrastructure questions that come with any serious AI adoption.

There's also a session on cybersecurity that sits squarely within the AI conversation: "Protecting Pharma: Ransomware, Social Engineering & Supply-Chain Threats," featuring the US Secret Service. As pharma organisations digitise more of their operations, the attack surface grows. That's not a reason to slow down, but it is a reason to build with security as a first principle rather than an afterthought.

The practical takeaway from this part of the agenda is that AI literacy is quickly becoming a baseline expectation across roles that wouldn't have considered it relevant two or three years ago. Organisations that are ahead of that curve will have a structural advantage.

‍

The CDMO space is getting more competitive

CDMOs are at the centre of this year's event in a way that reflects how central they've become to the broader pharma model. As more organisations lean on external manufacturing and development partners, the CDMO market has grown and so has the competition within it. Biologics, advanced therapies, and next-generation bio-manufacturing are all on the agenda, but the session that stands out is one on market strategy: "Future Market Strategy: Winning the Narrative as a Manufacturing Partner."

The title says a lot. When technical capability is broadly comparable across major players, differentiation comes down to how well an organisation communicates its strengths, builds trust with partners, and positions itself for the relationships that matter. That's a business development and leadership challenge as much as a scientific one.

For CDMOs attending, the value of this year's event isn't just in the sessions. The event has leaned into its role as a deal-making environment, with matchmaking built into the format and a gala that gives senior leaders a proper setting to build relationships rather than just exchange business cards.

‍

What all of this means for the people side of the business

Each of the themes running through CPHI Americas 2026 has a talent dimension that doesn't always get discussed alongside the science and strategy.

Regulatory upheaval creates immediate pressure on the professionals navigating it. Organisations that have the right regulatory and quality leadership in place can move faster and make better decisions when the environment is uncertain. Those that don't tend to find out the hard way.

The shift toward genuine AI adoption raises questions about skills and capability that most hiring processes aren't yet equipped to answer well. What does 'AI literacy' actually mean in a regulatory affairs or CMC role? How do you evaluate it? These are questions worth thinking through before you need to hire, not during.

And for CDMOs trying to win on narrative, the people making the case externally matter as much as the case itself. Commercial leadership, business development, and scientific communication are all areas where the right hire can shift how a company is perceived in the market.

None of that is unique to CPHI season. But events like this have a way of sharpening the focus and making it harder to defer conversations that probably should have happened sooner.

‍

If you're thinking about how your team is set up to navigate what's ahead, we work exclusively within the pharmaceutical sector and is happy to talk.